Intraoperative management of patients with carcinoid heart disease having valvular surgery: A review of one hundred consecutive cases

Toby N. Weingarten, Martin D. Abel, Heidi M. Connolly, Darrell R. Schroeder, Hartzell V Schaff

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

BACKGROUND: Cardiac surgery for carcinoid heart disease is complicated by hemodynamic instability secondary to carcinoid crises, cardiovascular dysfunction, and blood loss. The safety of vasopressors and the benefit of aprotinin during concomitant octreotide administration are uncertain. METHODS: We reviewed the effects of vasopressors and aprotinin on octreotide administration and mortality by univariate analysis in 100 consecutive cases of cardiac surgery for carcinoid heart disease from 1985 to 2003. Because mortality declines were temporally related to the introduction of aprotinin, bivariate analyses were performed to identify other factors associated with mortality. RESULTS: Carcinoid symptoms and hypotension were treated with octreotide (n = 89) and/or vasopressors (n = 93). Vasopressors were not associated with increased octreotide administration. Patients requiring epinephrine had higher mortality but also had worse preoperative New York Heart Association class, higher urinary 5-hydroxyindoleacetic acid levels, and increased blood transfusion requirements. Aprotinin (n = 54) was associated with decreased blood transfusion requirements, increased octreotide administration, but not mortality. Overall mortality was 13%, declining from 28% between 1985 and 1994 to 6% between 1995 and 2003. Mortality was associated with greater blood transfusion requirements and longer duration of cardiopulmonary bypass. CONCLUSIONS: Vasopressors may be used in conjunction with octreotide in carcinoid patients. The increased mortality associated with epinephrine likely reflects selection bias rather than a primary adverse effect. The improved survival over time in carcinoid patients is multifactorial and unrelated to aprotinin administration, suggesting further inhibition of the kallikrein-kinin system has little added benefit for this outcome in the presence of octreotide.

Original languageEnglish (US)
Pages (from-to)1192-1199
Number of pages8
JournalAnesthesia and Analgesia
Volume105
Issue number5
DOIs
StatePublished - Nov 2007

Fingerprint

Carcinoid Heart Disease
Octreotide
Aprotinin
Mortality
Carcinoid Tumor
Blood Transfusion
Epinephrine
Thoracic Surgery
Kallikrein-Kinin System
Hydroxyindoleacetic Acid
Selection Bias
Cardiopulmonary Bypass
Hypotension
Hemodynamics
Safety

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Intraoperative management of patients with carcinoid heart disease having valvular surgery : A review of one hundred consecutive cases. / Weingarten, Toby N.; Abel, Martin D.; Connolly, Heidi M.; Schroeder, Darrell R.; Schaff, Hartzell V.

In: Anesthesia and Analgesia, Vol. 105, No. 5, 11.2007, p. 1192-1199.

Research output: Contribution to journalArticle

Weingarten, Toby N. ; Abel, Martin D. ; Connolly, Heidi M. ; Schroeder, Darrell R. ; Schaff, Hartzell V. / Intraoperative management of patients with carcinoid heart disease having valvular surgery : A review of one hundred consecutive cases. In: Anesthesia and Analgesia. 2007 ; Vol. 105, No. 5. pp. 1192-1199.
@article{58c8860fcb28488486d8e40dc11812cd,
title = "Intraoperative management of patients with carcinoid heart disease having valvular surgery: A review of one hundred consecutive cases",
abstract = "BACKGROUND: Cardiac surgery for carcinoid heart disease is complicated by hemodynamic instability secondary to carcinoid crises, cardiovascular dysfunction, and blood loss. The safety of vasopressors and the benefit of aprotinin during concomitant octreotide administration are uncertain. METHODS: We reviewed the effects of vasopressors and aprotinin on octreotide administration and mortality by univariate analysis in 100 consecutive cases of cardiac surgery for carcinoid heart disease from 1985 to 2003. Because mortality declines were temporally related to the introduction of aprotinin, bivariate analyses were performed to identify other factors associated with mortality. RESULTS: Carcinoid symptoms and hypotension were treated with octreotide (n = 89) and/or vasopressors (n = 93). Vasopressors were not associated with increased octreotide administration. Patients requiring epinephrine had higher mortality but also had worse preoperative New York Heart Association class, higher urinary 5-hydroxyindoleacetic acid levels, and increased blood transfusion requirements. Aprotinin (n = 54) was associated with decreased blood transfusion requirements, increased octreotide administration, but not mortality. Overall mortality was 13{\%}, declining from 28{\%} between 1985 and 1994 to 6{\%} between 1995 and 2003. Mortality was associated with greater blood transfusion requirements and longer duration of cardiopulmonary bypass. CONCLUSIONS: Vasopressors may be used in conjunction with octreotide in carcinoid patients. The increased mortality associated with epinephrine likely reflects selection bias rather than a primary adverse effect. The improved survival over time in carcinoid patients is multifactorial and unrelated to aprotinin administration, suggesting further inhibition of the kallikrein-kinin system has little added benefit for this outcome in the presence of octreotide.",
author = "Weingarten, {Toby N.} and Abel, {Martin D.} and Connolly, {Heidi M.} and Schroeder, {Darrell R.} and Schaff, {Hartzell V}",
year = "2007",
month = "11",
doi = "10.1213/01.ane.0000284704.57806.0b",
language = "English (US)",
volume = "105",
pages = "1192--1199",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Intraoperative management of patients with carcinoid heart disease having valvular surgery

T2 - A review of one hundred consecutive cases

AU - Weingarten, Toby N.

AU - Abel, Martin D.

AU - Connolly, Heidi M.

AU - Schroeder, Darrell R.

AU - Schaff, Hartzell V

PY - 2007/11

Y1 - 2007/11

N2 - BACKGROUND: Cardiac surgery for carcinoid heart disease is complicated by hemodynamic instability secondary to carcinoid crises, cardiovascular dysfunction, and blood loss. The safety of vasopressors and the benefit of aprotinin during concomitant octreotide administration are uncertain. METHODS: We reviewed the effects of vasopressors and aprotinin on octreotide administration and mortality by univariate analysis in 100 consecutive cases of cardiac surgery for carcinoid heart disease from 1985 to 2003. Because mortality declines were temporally related to the introduction of aprotinin, bivariate analyses were performed to identify other factors associated with mortality. RESULTS: Carcinoid symptoms and hypotension were treated with octreotide (n = 89) and/or vasopressors (n = 93). Vasopressors were not associated with increased octreotide administration. Patients requiring epinephrine had higher mortality but also had worse preoperative New York Heart Association class, higher urinary 5-hydroxyindoleacetic acid levels, and increased blood transfusion requirements. Aprotinin (n = 54) was associated with decreased blood transfusion requirements, increased octreotide administration, but not mortality. Overall mortality was 13%, declining from 28% between 1985 and 1994 to 6% between 1995 and 2003. Mortality was associated with greater blood transfusion requirements and longer duration of cardiopulmonary bypass. CONCLUSIONS: Vasopressors may be used in conjunction with octreotide in carcinoid patients. The increased mortality associated with epinephrine likely reflects selection bias rather than a primary adverse effect. The improved survival over time in carcinoid patients is multifactorial and unrelated to aprotinin administration, suggesting further inhibition of the kallikrein-kinin system has little added benefit for this outcome in the presence of octreotide.

AB - BACKGROUND: Cardiac surgery for carcinoid heart disease is complicated by hemodynamic instability secondary to carcinoid crises, cardiovascular dysfunction, and blood loss. The safety of vasopressors and the benefit of aprotinin during concomitant octreotide administration are uncertain. METHODS: We reviewed the effects of vasopressors and aprotinin on octreotide administration and mortality by univariate analysis in 100 consecutive cases of cardiac surgery for carcinoid heart disease from 1985 to 2003. Because mortality declines were temporally related to the introduction of aprotinin, bivariate analyses were performed to identify other factors associated with mortality. RESULTS: Carcinoid symptoms and hypotension were treated with octreotide (n = 89) and/or vasopressors (n = 93). Vasopressors were not associated with increased octreotide administration. Patients requiring epinephrine had higher mortality but also had worse preoperative New York Heart Association class, higher urinary 5-hydroxyindoleacetic acid levels, and increased blood transfusion requirements. Aprotinin (n = 54) was associated with decreased blood transfusion requirements, increased octreotide administration, but not mortality. Overall mortality was 13%, declining from 28% between 1985 and 1994 to 6% between 1995 and 2003. Mortality was associated with greater blood transfusion requirements and longer duration of cardiopulmonary bypass. CONCLUSIONS: Vasopressors may be used in conjunction with octreotide in carcinoid patients. The increased mortality associated with epinephrine likely reflects selection bias rather than a primary adverse effect. The improved survival over time in carcinoid patients is multifactorial and unrelated to aprotinin administration, suggesting further inhibition of the kallikrein-kinin system has little added benefit for this outcome in the presence of octreotide.

UR - http://www.scopus.com/inward/record.url?scp=37349079170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349079170&partnerID=8YFLogxK

U2 - 10.1213/01.ane.0000284704.57806.0b

DO - 10.1213/01.ane.0000284704.57806.0b

M3 - Article

C2 - 17959940

AN - SCOPUS:37349079170

VL - 105

SP - 1192

EP - 1199

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 5

ER -